Page 41 - Read Online

Orekhov et al. Vessel Plus 2019;3:3 I http://dx.doi.org/10.20517/2574-1209.2018.80 Page 11 of 14

triggers atherogenesis at the cellular level. This knowledge should lead to the development of fundamentally
new approaches to the diagnosis of atherosclerotic diseases, but unfortunately extensive research in this
direction is not carried out. On the other hand, new developments based on foam cells and LDL were
translated into clinics as therapeutic tools. Using cell models and natural products, an approach has been
developed to prevent the formation of foam cells. This is an example of how the results of basic research have
been successfully translated into clinical practice. Drugs with direct anti-atherosclerotic activity have been
developed. These drugs cause regression of atherosclerosis and/or prevention of its progression in patients.

DECLARATIONS
Authors’ contributions
All authors contributed equally to the article.

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by Russian Science Foundation (18-15-00254).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Sobenin IA, Galitsyna EV, Grechko AV, Orekhov AN. Small dense and desialylated low density lipoprotein in diabetic patients. Vessel
Plus 2017;1:29-37.
2. Alipov VI, Sukhorukov VN, Karagodin VP, Grechko AV, Orekhov AN. Chemical composition of circulating native and desialylated low
density lipoprotein: what is the difference? Vessel Plus 2017;1:107-15.
3. Takahashi S. Triglyceride rich lipoprotein -LPL-VLDL receptor and Lp(a)-VLDL receptor pathways for macrophage foam cell
formation. J Atheroscler Thromb 2017;24:552-9.
4. Lehti S, Nguyen SD, Belevich I, Vihinen H, Heikkilä HM, et al. Extracellular lipids accumulate in human carotid arteries as distinct
three-dimensional structures and have proinflammatory properties. Am J Pathol 2018;188:525-38.
5. Orekhov AN, Ivanova EA, Bobryshev YV. Naturally occurring multiple-modified low-density lipoprotein. In: Ruiz M, editor. Blood
lipids and lipoproteins. New York: Nova Science Publishers Inc.; 2015. pp. 13-54.
6. Allahverdian S, Chaabane C, Boukais K, Francis GA, Bochaton-Piallat ML. Smooth muscle cell fate and plasticity in atherosclerosis.
Cardiovasc Res 2018;114:540-50.
7. Kruth HS. Receptor-independent fluid-phase pinocytosis mechanisms for induction of foam cell formation with native low-density
lipoprotein particles. Curr Opin Lipidol 2011;22:386-93.
8. Kruth HS, Jones NL, Huang W, Zhao B, Ishii I, et al. Macropinocytosis is the endocytic pathway that mediates macrophage foam cell
formation with native low density lipoprotein. J Biol Chem 2005;280:2352-60.
9. Orekhov AN, Ivanova EA, Melnichenko AA, Sobenin IA. Circulating desialylated low density lipoprotein. Cor Vasa 2017;59:e149-56.
10. Orekhov AN, Sobenin IA. Modified lipoproteins as biomarkers of atherosclerosis. Front Biosci (Landmark Ed) 2018;23:1422-44.
11. Orekhov AN, Tertov VV, Mukhin DN, Koteliansky VE, Glukhova MA, et al. Association of low-density lipoprotein with particulate
connective tissue matrix components enhances cholesterol accumulation in cultured subendothelial cells of human aorta. Biochim